Leta i den här bloggen

Visar inlägg med etikett Afrikan Ebola. Visa alla inlägg
Visar inlägg med etikett Afrikan Ebola. Visa alla inlägg

fredag 3 augusti 2018

WHO bulletin kertoo ebolapurkauksista

There has been an eerie mirroring of events between the ongoing outbreak of Ebola virus disease in the Democratic Republic of the Congo (DRC) and the 2014–15 outbreak in Liberia. The DRC has vast historical experience from containing eight prior outbreaks, but the country has not previously had to respond to urban Ebola spread.
The current and ninth DRC outbreak was declared by the Ministry of Health on May 8, 2018.
1
By May 14, Ebola virus had escaped the rural epicentre of Bikoro and travelled 150 km into Mbandaka, an urban centre populated by 1·2 million people.
1
In a similar manner, during late June, 2014, Ebola virus disease escaped rural Sierra Leone into Foya District of rural Liberia and proceeded to enter the densely populated New Kru Town community of Monrovia, a city of over 1 million inhabitants.
2
The unprecedented case counts of the west African epidemic were largely due to this unprecedented migration into unprepared urban centres. At the height of the outbreak in September, 2014, Monrovia alone was accounting for 51% of all the Ebola cases in Liberia. Given the parallel scenario of cases emerging in Mbandaka, the response in the upcoming weeks and its sensitivity to the local context will be critical in informing the final outbreak size in the DRC.
Understanding the cause of spread in Liberia provides important lessons for the DRC. Why did the index urban case decide to leave Bikoro for Mbandaka?
First, to seek care. She may have come to the city to seek medical care since care in her village was inadequate and she was observing others die in spite of the treatment they were receiving. Given this root cause of movement, case investigation should hone in on hospitals and clinics visited for treatment to identify highest risk contacts. In Liberia, Monrovia's case zero in 2014 visited Redemption Hospital and exposed nurses and a doctor. Some of those exposed at Redemption Hospital went to a clinic in a neighbouring community and infected two nurses, who themselves sought treatment in another community and infected multiple health-care workers.
Second, it is also possible the case left her village to evade cultural threats. If she fled to the city since she attributed her illness to supernatural cause, such as a curse, it could have led her to relatives in Mbandaka with anticipation of finding a spiritual solution from traditional healers. In late June, 2014, migration to Monrovia in response to Ebola disease as a perceived curse prompted the second wave of transmission. A 16-year-old girl from a village in Sierra Leone had seen her family members systematically die from a strange disease. The prevailing belief was that the girl and her family were bewitched since their grandfather stole a goat. In pursuit of a spiritual solution, she and her brother drove to Monrovia from Sierra Leone, leading to cross–border transmission and a large disease cluster in densely populated Monrovia.
In light of these motivations, how can a trustworthy and trusted response be delivered to control the spread of the virus (panel)?
Panel
Five actions for delivering a trusted response for the control of Ebola virus transmission
  • Provide sufficient point-of-need care to prevent rural to urban spread
  • Implement and laud successful treatment innovations
  • Debunk rumours and generate data through community engagement
  • Balance public health with individual rights
  • Practice safe burials
First, sufficient point-of-need care should be provided to prevent rural to urban spread. Access to effective health-care for diagnosis and case management will shift the disbelief and distrust around Ebola and prevent outward migration. Rules barring people from travelling in and out of villages will then be possible.
Second, successful treatment innovations should be implemented and lauded. In Liberia, all patients entering Ebola treatment units (ETUs) were given an intravenous line for fluid administration. Some patients also received ZMapp, a putative immunotherapy for Ebola virus disease.
3
A positive feedback loop is essential for building trust in ETU care. Survivors should be paraded in communities to emphasise the role of ETUs in saving lives.
Third, through community engagement, rumours need to be debunked and data generated. Community youth, pastors, and imams should be trained in conducting daily door-to-door surveillance on visitors, the sick, and potential dead.
4
The communication should be horizontal rather than vertical. The resulting data will govern the response by guiding distribution of ambulances, burial teams, and food for affected homes.
Fourth, public health priorities must be balanced with consideration for individual rights. No patients in the ETU should be allowed to leave until certified as being clear of Ebola virus.
Finally, practicing safe burials is essential. Local community leaders, religious leaders, and youth leaders should be mobilised to identify secret deaths and burials so that the dead body management teams can conduct safe and dignified burials. In Liberia, a Muslim burial team was formed to handle bodies in protective suits while allowing the appropriate ablutions.
At a macrocosmic level, the relationship between virulence and transmissibility is perturbed by population–level beliefs and practices. Beyond the establishment of ETUs and targeted vaccination, understanding root causes of disease emergence in urban DRC will be essential to preventing additional rural to urban spread and to containing the outbreak within urban centres.
We declare no competing interests.
 
References
    WHO Regional Office for Africa
Ebola Virus Disease: Democratic Republic of Congo. External situation report 2.
  • Nyenswah, T
  • Fahnbulleh, M
  • Massaquo, M
  • et al.
Ebola epidemic—Liberia, March–October 2014.
MMWR Morb Mortal Wkly Rep. 2014; 63: 1082-1086
    PREVAIL II Writing Group, for the Multi-National PREVAIL II Study Team
A randomized, controlled trial of ZMapp for Ebola virus infection.
N Engl J Med. 2016; 375: 1448-1456
  • Fallah, M
  • Dahn, B
  • Nyenswah, TG
  • et al.
Interrupting Ebola transmission in Liberia through community–based initiatives: interrupting Ebola transmission in Liberia.
Ann Intern Med. 2016; 164: 367-369
Article Info
Publication History
IDENTIFICATION
DOI: 10.1016/S0140-6736(18)31435-1

tisdag 13 januari 2015

Ebolastatistiikka 4.1. 2015

http://www.who.int/csr/disease/ebola/situation-reports/en/
Näkyy tulleen uusimmat tilastolliset luvut WHO:lta:

 Yleisvaikutelma olisi , että purkaus on  vähtiellen katoamassa taas jonnekin  reservoaariinsa - virus on saanut vahvistettua geenimateriaalinsa  tai  piilevä vastustuskyy alkaa  olla jossain olemassa. Luonnollisesti  koko maailman hoitova  panos tilanteeseen vaikuttaa myös tätä  hyvää suuntaa.

Guinea : Kaikki tapaukset 2775. Kuolleet 1781. Mortaliteettiprosentti  64.2 %
Liberia kaikki tapaukset 8157. Kuolleet 3496. Mortaliteetti 42.9%
Sierra Leone kaikki  tapaukset 9760. Kuolleet  2943.  Mortaliteetti  30.2 %.
Mali  8 tapausta, kuolleet 6. Mortaliteetti  70%
Nigeria 20 tapausta. Kuolleet 8. Mortaliteetti prosentti  75%.
Senegal  1 tapaus, ei kuolleita.
Espanja 1 tapaus. ei kuolleita.
UK 1 tapaus. ei kuolleita.
USA 4 tapausta. 1 kuollut ( mortaliteetti  25%.

Koska virus lie aika samanlainen kaikissa, mortaliteetti numero(%)  varsinaisesti johtunee  myös paljolti ulkoisista tekijöistä, hoitolinjasta  ja statistiikan  luonnollisista virhelähteistä - siitä että kaikkia tapauksia ei saada tietoon. Kaikkien  varmojen tapausten mortaliteetiprosentiksi saa  39,7%., mutta se voi olla korkeampi.

Liberian mortaliteeti on lähinnä sitä keskimääräistä  lukua.
 Mortaliteetin seuraminen  sinänsä on kiinnostava,  koska siitä  heijastunee, jos virus  hankkii lisäkapasieetteja yhtäkkiä. Jos se ei niitä saa, niin yhteiskunnan  vasta-aineitten kehittymisen myötä pitäisi mortaliteetin  osoittaa  vähenemistä suuressa luvussa minun mielestäni.  Mutta jos  realistisesti ajattelen ebolavirusta, se on  robusti, joka  luottaa infektiivisyydessä siihen että se ei kohtaa  spesifisiä valmiita vasta-aineita tai valmiiksi viritettyä immuunivastetta.  Sitä paitsi, ne alueet missä  vasta-aineita  on aiemmista vuosista, eivät nyt ole  altistuneita.  samalla tavalla.
 Ja jotta virus  kykenee toisen kerran  yhtä  rajuun expansioon,  sen täytyy muuntua sipposemmaksi, vielä katalammaksi,  mutta nyt taitaa ehtiä rokotus avuksi ennen kuin seuraava koitos tulee.  Sitä paitsi reservoaarisaneerauskin voidaan tehdä  vuosien aikana.  Ebolaa ei saa enä unohtaa kuten entisten purkausten jälkeen vain eräänlaiseksi mstan pilven kuvaksi arkistoon. .
Asunnotkin pitäisi siivota rotista mm ja lattiat  tehdä sellaisiksi että  siellä ei vilise lämminverisiä jyrsijöitä.  tai roiku katoista niinkuin  erään maan kouluhuoneissa.  Tietty on paljon  mitä voidaan tehdä.
Sitä paitsi mitä statistiikkaan tulee,  diagnosointi on sinnsä elintärkeä globaaliterveyden kannalta, eikä  statistiikan numerotietojen täyttämsien kannalta.  Mutat  tilanteen luotaimena tietojen saaminen statistiikaksi antaa jonkinlaista realiteettitestiä , sillä hoito on  "raskaan sarjan keijukaisten työtä" - vatimus on valtava,  vain harva täyttää vaatimuset . Moni  käytännön tekijä taas ei ole mikään  toimistokirjuri vaan hengenpelastaja. Joten  statistiikalle antautuneitenkin  panos on  hyvin olennainen ja arvostettu, vaikka henkilö ei itse omin silmin näkisikään ebolaa.


fredag 4 mars 2011

Afrikan Ebolavirus aiheuttaa verenvuotokuumetta. Filippiinien Reston Ebolavirus ei.

  • LÄHDE 1.
Dr Heinz Feldmann MD a b, Thomas W Geisbert PhD cEbola haemorrhagic fever
The Lancet, Volume 377, Issue 9768, Pages 849 - 862, 5 March 2011
doi:10.1016/S0140-6736(10)60667-8Cite or Link Using DOI
Published Online: 16 November 2010

Summary

Ebola viruses are the causative agents of a severe form of viral haemorrhagic fever in man, designated Ebola haemorrhagic fever, and are endemic in regions of central Africa. The exception is the species Reston Ebola virus, which has not been associated with human disease and is found in the Philippines.

Ebola virus constitutes an important local public health threat in Africa, with a worldwide effect through imported infections and through the fear of misuse for biological terrorism.

Ebola virus is thought to also have a detrimental effect on the great ape population in Africa. Case-fatality rates of the African species in man are as high as 90%, with no prophylaxis or treatment available.Ebola virus infections are characterised by

  • immune suppression and
  • a systemic inflammatory response that causes
  • impairment of the vascular, coagulation, and immune systems,
  • leading to multiorgan failure and shock,
  • and thus, in some ways, resembling septic shock.
Lancet

  • LÄHDE 2. 

Siddhartha Mahanty a, Dr Mike Bray b
Pathogenesis of filoviral haemorrhagic fevers
The Lancet Infectious Diseases, Volume 4, Issue 8, Pages 487 - 498, August 2004
doi:10.1016/S1473-3099(04)01103-XCite or Link Using DOI

Summary

The filoviruses, marburgvirus and ebolavirus, cause epidemics of haemorrhagic fever with high casefatality rates.

The severe illness results from a complex of pathogenetic mechanisms that enable the virus
  • to suppress innate and adaptive immune responses,
  • infect and kill a broad variety of cell types,
  • and elicit strong inflammatory responses
  • and disseminated intravascular coagulation (DIC),
  • producing a syndrome resembling septic shock.
Most experimental data have been obtained on Zaire ebolavirus, which causes uniformly lethal disease in experimentally infected non-human primates but produces a broader range of outcomes in naturally infected human beings.
10—30% of patients can survive the illness by mobilising adaptive immune responses, and there is limited evidence that mild or symptomless infections also occur.

The other filoviruses that have caused human disease, Sudan ebolavirus, Ivory Coast ebolavirus, and marburgvirus, produce a similar illness but with somewhat lower case-fatality rates.

Variations in outcome during an epidemic might be due partly to genetically determined differences in innate immune responses to the viruses.
  • Recent studies in non-human primates have shown that blocking of certain host responses, such as the coagulation cascade, can result in reduced viral replication and improved host survival.